

Prior Authorization Request Form for Opioid Dependence Treatment

FAX this completed form to (844) 205-3386

OR Mail requests to: Pharmacy Department | 5 River Park Place East, Suite 210 | Fresno, CA 93720 OR Prior authorization may be completed at https://www.covermymeds.com/main/prior-authorization-forms/

I. PROVIDER INFORMATION		II. MEMBER INFOR	RMATION	
Prescriber Name:		Member Name:		
Prescriber Specialty:		Identification #:		
NPI:		Group #:		
Office Contact Name:		Date of Birth:		
Fax #:		Medication Allergies:		
Phone #:				
III. DRUG INFORMATION (One drug	request per form	1)		
Drug name and strength:	Dosage Interval (sig	g):	Qty. per Day:	
IV. REQUIRED DOCUMENTION (Detailer must be submitted with prior of			lemonstrating evidence for each	
Specify diagnosis & diagnosis code relevant to this request: Dx/Dx Code:				
Does the member have a history of contra medication?	nindication to the pre	escribed	Submit documentation.	
Did the prescriber or prescriber's delegate search the PDMP to review the member's controlled substance prescription history before issuing this prescription for the requested agent? Yes Submit documentation. No				
☐ If requesting for daily quantity exceeding daily limit (Refer to https://www.dhs.pa.gov/providers/Pharmacy-Services/Pages/Quantity-Limits-and-Daily-Dose-Limits.aspx), please provide supporting information:				
SUBMIT MEDICAL RECORD INFORMATION FOR EACH APPLICABLE ITEM.				
LUCEMYRA: — Prescribed a dose and duration of therapy consistent with FDA-approved package labeling, nationally recognized				
Prescribed a dose and duration of compendia, or peer-reviewed med		vitn FDA-approved pac	kage labeling, nationally recognized	
BUPRENORPHINE WITHOUT NALOXONE:				
☐ Member meets one of the following:				
☐ Prescribed for induction therapy				
Pregnant				
☐ Breastfeeding				
History of contraindication or intolerance to naloxone				
NON-PREFERRED OPIOID DEPENDENCE TREATMENT: Oral Buprenorphine, has a therapeutic failure, contraindication or intolerance to the preferred oral buprenorphine				
Opioid Dependence Treatment:				
Alpha-2 Adrenergic Agonist, has a therapeutic failure, contraindication or intolerance to the preferred alpha-2 adrenergic agonist Opioid Dependence Treatment:				
Non-Oral Buprenorphine, has a therapeutic failure, contraindication or intolerance to the preferred non-oral buprenorphine Opioid Dependence Treatment:				
REQUEST FOR ORAL BUPRENORPHINE ABOVE 24MG PER DAY:				
 □ Prescribed daily dose is consistent with medically accepted prescribing practices and standard of care □ Documentation of an evaluation to determine the recommended level of care 				

 □ Documentation of member is in a substance abuse or addiction recovery program REQUEST FOR ORAL BUPRENORPHINE ABOVE 24MG PER IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII	DAY (CONTINUED): al for abuse has a recent urine drug screen positive for				
IV. ADDITIONAL RATIONALE FOR REQUEST / PERTINENT CLINICAL INFORMATION :					
Appropriate clinical information to support the request on the basis of medical necessity must be submitted.	Provider Signature:	Date:			

Pharmacy Department will respond via fax or phone within 24 hours.
Requests for prior authorization (PA) requests must include member name, ID#, and drug name. Please include lab reports with requests when appropriate (e.g., Culture and Sensitivity; Hemoglobin A1C; Serum Creatinine; CD4; Hematocrit; WBC, etc.)